Put Options

15 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2022

Oct 25, 2022

SELL
$61.1 - $83.78 $513,240 - $703,752
-8,400 Reduced 42.86%
11,200 $474,000
Q2 2022

Aug 04, 2022

SELL
$43.23 - $73.83 $354,486 - $605,406
-8,200 Reduced 29.5%
19,600 $639,000
Q1 2022

Apr 14, 2022

SELL
$53.19 - $79.24 $569,133 - $847,868
-10,700 Reduced 27.79%
27,800 $1.01 Million
Q4 2021

Jan 18, 2022

BUY
$70.09 - $111.29 $1.6 Million - $2.54 Million
22,800 Added 145.22%
38,500 $1.19 Million
Q3 2021

Oct 26, 2021

SELL
$110.2 - $156.64 $22,040 - $31,327
-200 Reduced 1.26%
15,700 $623,000
Q2 2021

Jul 19, 2021

BUY
$100.84 - $161.89 $413,444 - $663,749
4,100 Added 34.75%
15,900 $476,000
Q1 2021

Apr 26, 2021

BUY
$110.72 - $210.04 $132,864 - $252,048
1,200 Added 11.32%
11,800 $587,000
Q4 2020

Jan 21, 2021

BUY
$79.67 - $173.23 $772,799 - $1.68 Million
9,700 Added 1077.78%
10,600 $352,000
Q3 2020

Oct 27, 2020

BUY
$78.5 - $100.64 $31,400 - $40,256
400 Added 80.0%
900 $12,000
Q4 2018

Feb 05, 2019

SELL
$22.73 - $42.34 $59,098 - $110,084
-2,600 Reduced 83.87%
500 $9,000
Q3 2018

Nov 07, 2018

BUY
$44.35 - $65.71 $39,915 - $59,138
900 Added 40.91%
3,100 $33,000
Q2 2018

Aug 10, 2018

SELL
$42.62 - $73.59 $234,410 - $404,745
-5,500 Reduced 71.43%
2,200 $2,000
Q1 2018

May 11, 2018

BUY
$23.52 - $58.17 $134,064 - $331,569
5,700 Added 285.0%
7,700 $15,000
Q4 2017

Jan 17, 2018

SELL
$16.95 - $23.48 $45,765 - $63,396
-2,700 Reduced 57.45%
2,000 $0
Q3 2017

Oct 17, 2017

BUY
$16.75 - $20.66 $78,725 - $97,102
4,700
4,700 $4,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $4.28B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.